Global Urinalysis Market Size

Urinalysis Market Analysis

The urinalysis market is expected to register a CAGR of 7.5% over the forecast period.

The outbreak of COVID-19 impacted the urinalysis market, as hospitals and healthcare services restricted services due to social distancing measures. The unprecedented increase in coronavirus-infected patients reduced access to other primary care services and resulted in a significant drop in non-COVID-19-related diagnoses, such as urinary tract infections or kidney diseases. For instance, according to a research article published in the International Journal of Surgery in July 2021, during the COVID-19 pandemic, urological procedures delayed or postponed included urinary tract infections, stress incontinence, overactive bladder (OAB), and neurogenic bladder. Similarly, according to a December 2021 study published in the ADIAN Journal, fewer patients adopted primary care services, and fewer diagnoses were done, including UTIs. The source also reports that between March 30 and April 24, 2020, the weekly rate of UTI diagnosis per 100,000 population fell from an average of 30-35 to less than 10 in England. Since April, the rate has risen by 50% of the usual rate. Thus, the market witnessed an adverse impact during the pandemic. However, with the ease of restrictions and declining cases of COVID-19, the market started to gain momentum and is expected to continue the upward trend over the forecast period.

The higher burden of chronic diseases such as diabetes and chronic kidney diseases and the rising adaptation of point-of-care testing is expected to be the major contributing factors to the market growth. Urinary tract infection refers to an infection in any part of the urinary system. For instance, as per a December 2021 update by the International Diabetes Federation (IDF), in 2021, approximately 537.0 million adults (20-79 years) had diabetes, which is projected to rise to 643.0 million by 2030 and 783.0 million by 2045. As per the same source, 3 in 4 adults with diabetes live in low- and middle-income countries and almost 1 in 2 (240 million) of them are undiagnosed. The source also reports that diabetes caused 6.7 million deaths in 2021. To identify the glucose level in diabetic people, urine analysis has proven to be an important test. 

Furthermore, increasing cases of chronic kidney diseases across the globe are also expected to propel market growth over the forecast period. For instance, chronic kidney disease (CKD) is a condition that causes reduced kidney function over some time. It may develop over many years and lead to end-stage kidney (or renal) disease (ESRD). It has become an enormous public health issue. For instance, as per the 2021 report by the CDC, more than 15.0% of adults in the United States, amounting to approximately 37.0 million people, were estimated to have CKD. Similarly, in 2021, as per data released on World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), kidney disease affected around 850.0 million people globally. The same source also reported that one in ten adults has chronic kidney disease (CKD). The global burden of CKD is continuously increasing and is projected to become the 5th most common cause of years of life lost globally by 2040. 

While the market is poised for growth, stringent regulatory frameworks related to urinalysis may hinder market growth over the forecast period.